Having trouble viewing this email? View in your browser.
ESCMID Logo

2 August 2017
WEEKLY NEWS

Dear colleagues,

The abstract submission deadline for the 4th ESCMID Conference on Vaccines - New and old diseases in children and adults - unmet needs has been extended to 28 August. Register now!

Your ESCMID communications editors

 

Deadline for call for abstracts extended: 28 August 2017

Submit your abstract and share and discuss your research with colleagues from around the world at the Vaccines Conference in Dubrovnik!


› Read more
 

Expert commentary on the importance of setting up antibiotic stewardship teams worldwide to halt the spread of dangerous infections

An ESGAP expert commentary in Clinical Microbiology and Infection discussed the urgent need to plan and fund teams of specialist health workers to promote appropriate antibiotics use. Ideally, such teams should consist of ID specialists, microbiologists, nurses and pharmacists. Together, their collaborative effort can improve diagnosis and treatment of infections as well as prevent the rise of drug-resistant bacteria. 

Link to the full press release  and the expert opinion piece

› Read more
 

Summer School 2017: yet another success story

From 1-8 July another edition of our yearly Summer School was held in Borstel, Germany. A record-breaking 80 participants from 26 countries enjoyed the excellent lectures by renowned experts in the field and have taken the opportunity to network with their peers in a relaxed setting.

Please find all presentations here. Also, take a glimpse at the picture gallery here

The Summer School next year will take place in Paris in July 2018. We will let you know once more information is available. 

› Read more
 

Systematic review and meta-analysis to determine susceptibility of clinical C. difficile isolates to antimicrobials

Khanafer et al aimed to describe publication patterns relating to C. difficile susceptibilities and estimate minimum inhibitor concentrations (MIC) for antibiotic classes described in the scientific literature between January 1970 and June 2014. They found that aminoglycosides (IC50: 120mg/L, 95%CI: 62-250), 3rd (MIC50: 75mg/L, 95%CI: 39-130) and 2nd generation (IC50: 64mg/L, 95%CI: 27-140) cephalosporins had the least C. difficile activity, while rifamycins (IC50 : 0.034mg/L, 95%CI: 0.012-0.099) and tetracyclines (MIC50: 0.29mg/L, 95%CI: 0.054-1.7) had the highest, resulting in a 3500-fold variation between the least and most active agents. Furthermore, time-trends in MIC50 were increasing for carbapenems (70% per 10 years) while they were decreasing for tetracyclines (51% per 10 years). Future research initiatives will address how these in vitro measures can help to reliably estimate the risk for C. difficile infection and guide antimicrobial stewardship decisions.

› Read more
 

Inventory of target indicators assessing antibiotic prescriptions

Antibiotics prescription behaviour in Europe was assessed in a cross-sectional study aimed at making an inventory of indicators linked to specific targets and incentives at the national level. The study found that of all responding countries, only Croatia and Turkey used computerized systems routinely linking antibiotic prescriptions to clinical diagnosis. In six of the remaining 21 countries, national indicators with clear targets and incentives were in place. Similar targets and incentives were reported at the regional level in e.g. Spain and England. Of the total number of indicators (n=21), 16 concerned inpatients and 8 outpatients (some used in both settings). Incentives included financing mechanisms, hospital accreditation and public reporting. In order to continue to assess antibiotic prescription behaviour and share experience between countries, the authors suggest to set up a European database.

› Read more
 

The ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

ASM and ESCMID partner again in 2017 for the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. This conference showcases and explores a variety of topics treating antimicrobial resistance, from drug development to regulation practices. Join us and hear from your peers from around the globe in Boston, Massachusetts, 6 - 8 September at the Boston Park Plaza Hotel. When you register for ASM/ESCMID 2017 it includes access to the complimentary Pre-Conference Workshop: Antibiotic Development Bootcamp on 5 September. 

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.